GenVec receives grant to support its malaria vaccine program
The $600,000 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health will be used to identify highly protective and novel antigens for developing malaria vaccines.
"We appreciate the support this grant offers GenVec," Joseph Bruder, GenVec's director of research and the head of the company's malaria program, said. "Our technology to discover new antigens is showing promise and this grant will further our efforts in this area to identify novel antigens for malaria vaccine development."
The work under the grant will build on research that was started under a 2009 NIAID Small Business Innovation and Research Grant. GenVec will collaborate with the Naval Medical Research Center to apply its adenovector technology to the creation of candidates for malaria vaccines.
GenVec works with organizations and companies such as Merial, Novartis and the U.S. government to support multiple product programs addressing the treatment and prevention of significant animal and health concerns. The company's programs include the creation of vaccines to protect against respiratory syncytial virus, herpes simplex virus, dengue fever, human immunodeficiency virus and malaria. In animal health, the company is developing vaccines against foot-and-mouth disease.